FP14.07 Combination Osimertinib plus Selpercatinib for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) with Acquired RET fusions
Julia Rotow, Jyoti D. Patel, Matthew P. Hanley, Helena A. Yu, Jonathan H. Goldman, H. Nechustan, Matthias Scheffler, Mark M. Awad, Sarah Clifford, Alison Santucci, Larissa Leopoldino da Silva, Rebecca Tupper, Geoffrey R. Oxnard, Jennifer Kherani, Alexander Drilon
Topics & Concepts
OsimertinibMedicineLung cancerCancer researchOncologyMutantInternal medicineEpidermal growth factor receptorCancerGeneErlotinibBiologyGeneticsLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesGastric Cancer Management and Outcomes